Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.93 USD

68.93
3,935,175

+0.18 (0.26%)

Updated Sep 4, 2024 04:00 PM ET

After-Market: $68.93 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

    Here's Why You Should Add Chemed (CHE) to Your Portfolio

    Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

      Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

      BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

        Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

        Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

          Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

          Neogen (NEOG) rides high on balanced growth across all business segments.

            Halyard Health (HYH) Announces Positive Data on COOLIEF

            Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.

              Surmodics Receives FDA's Approval for PTA Balloon Catheter

              Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

                Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

                  Myriad Genetics Presents Favorable riskScore Test Data

                  Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.

                    McKesson to Gain From Distribution Business Amid Pricing Woes

                    McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.

                      Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

                      Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.

                        Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare

                        Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.

                          NuVasive Launches Breakthrough in MIS Surgery -- LessRay

                          NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.

                            Genomic Health Ties up With Biocartis, Boosts Oncotype DX

                            Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.

                              Fresenius Medical Opens Manufacturing Plant in Malaysia

                              Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

                                Amedisys Rides High on Strong Prospects Amid Margin Woes

                                Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.

                                  Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

                                  Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                                    IDEXX Laboratories Rides High on Strong CAG, Global Growth

                                    IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.

                                      Medtronic Launches StealthStation Technology, Expands in ENT

                                      Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.

                                        AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                        AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.

                                          CVS Health Gains on Pharmacy Services, Retail Remains a Drag

                                          CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.

                                            Quotient Limited (QTNT) in Focus: Stock Moves 30.3% Higher

                                            Quotient Limited (QTNT) saw its shares rise over 30% on the day.

                                              Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag

                                              Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.

                                                Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well

                                                Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.

                                                  Why the Earnings Streak Will Continue for Edwards Lifesciences (EW)

                                                  Edwards Lifesciences (EW) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.